PT  - JOURNAL ARTICLE
AU  - Ming Liu
AU  - Lixia Zheng
AU  - Chen He
AU  - Jun Xu
TI  - Overcome the EGFR-TKIs resistance with cucurbitacin BE compound by targeting STAT3, ERK1/2 and AKT
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - 4545
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/4545.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/4545.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) is highly sensitive to EGFR tyrosine kinase inhibitors (TKIs) therapy, but acquired resistance eventually develops at about 9-12 months. Overcoming the drug resistance is of great clinical and scientific significance. In this study, We showed that STAT3,ERK1/2 and AKT were persistently activated in the resistant cells with T790M mutation(PC9/ER) and 52 tumor samples from EGFR-TKIs resistant NSCLC patients.The growth inhibition of the triterpenoid compound cucurbitacin BE (Cu BE) was tested in vitro and in vivo against PC9/GR cells. Cu BE can inhibit the growth of PC9 and PC9/GR cells in a dose- and time-dependent manner, resulting in G2/M phase arrest and apoptosis. This was associated with inhibition of activated Stat3,ERK1/2 and AKT, increased level of autophagy(LC3B expression), and down-regulated the expression of caspase 3 and survivin. Moreover, in a nude mouse tumor xenograft model, Cu BE decreased the PC9/GR tumor volume by 46.4% (P < 0.05) compared with the mice treated with erlotinib. These data suggest that treatment with CuBE, which can inhibite the activation of STAT3,ERK1/2 and AKT, appears to be an effective strategy for NSCLC patients with EGFR-TKIs resistance.